التفاصيل البيبلوغرافية
| العنوان: |
A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Tong Luo Hua Shi capsule, a modernized Tibetan medicine, in patients with rheumatoid arthritis. |
| المؤلفون: |
Wei Liu, Yuan-Hao Wu, Si-Yuan Hu, Cheng-Liang Zhong, Ming-Li Gao, Dong-Wu Liu, Hai-Yun Wang, Mu-Zhi Chen, Yue-Jin Song, Ben-Zha-Xi Yang, Qing-Shan Zheng, Hua Yao, Xue-Bing Qi, Gang Li, Liu, Wei, Wu, Yuan-Hao, Hu, Si-Yuan, Zhong, Cheng-Liang, Gao, Ming-Li, Liu, Dong-Wu |
| المصدر: |
Trials; 7/27/2016, Vol. 17, p1-7, 7p, 1 Diagram, 4 Charts |
| مصطلحات موضوعية: |
RHEUMATOID arthritis treatment, TREATMENT of arthritis, JOINT disease treatment, TIBETAN medicine, ASIAN medicine, RHEUMATOID arthritis diagnosis, ANTIRHEUMATIC agents, PHARMACEUTICAL encapsulation, COMPARATIVE studies, CONVALESCENCE, FUNCTIONAL assessment, HERBAL medicine, RESEARCH methodology, MEDICAL cooperation, CHINESE medicine, ORAL drug administration, RESEARCH, RHEUMATOID arthritis, TIME, EVALUATION research, PAIN measurement, RANDOMIZED controlled trials, TREATMENT effectiveness, BLIND experiment, DRUG administration, DRUG dosage |
| مصطلحات جغرافية: |
CHINA |
| مستخلص: |
Background: Tong Luo Hua Shi (TLHS) is a new formulation of the traditional Tibetan medicine Wu-wei-gan-lu that has been used for the treatment of rheumatoid arthritis (RA) for hundreds of years in China. This study aimed to evaluate the efficacy and safety of TLHS in patients with RA.Methods: This was a randomized, double-blind, placebo-controlled, dose-finding study performed in patients with active RA from five medical centers. Patients received three doses (4.8, 3.6, or 2.4 g/day po) of TLHS or placebo (tid po) for 8 weeks. Blood sampling, physical examination, and assessment of the American College of Rheumatology (ACR) 20 % improvement (ACR20) criteria were performed before and every 2 weeks after starting treatment. The primary endpoint was the ACR20. The secondary endpoints included safety.Results: A total of 240 participants were screened and 236 patients were randomized (n = 59/group); 20 dropped out. After 8 weeks, ACR20 improvements in the TLHS 4.8 g and 3.6 g groups were significantly higher than in the placebo group (P < 0.01 and P < 0.05, respectively). ACR50 improvement in the TLHS 4.8 g group was significantly higher compared with the placebo group (P < 0.01). Symptoms of RA were significantly relieved in the TLHS groups. In the TLHS groups, insomnia (n = 1), gastroenteric reactions (n = 2), arrhythmia (n = 1), and minor hepatic lesion (n = 1) were reported; in the placebo group, hepatic dysfunction (n = 1) was reported (P = 0.878).Conclusions: TLHS improved the symptoms of patients with RA according to the ACR20. Moreover, TLHS was safe.Trial Registration: Chinese Clinical Trial Registry: ChiCTR-TRC-12003871 . Registered on 1 January 2012. [ABSTRACT FROM AUTHOR] |
|
Copyright of Trials is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder